Suppr超能文献

人乳腺癌细胞系中的纤溶酶原激活剂:激素调节与特性

Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties.

作者信息

Mangel W F, Toledo D L, Nardulli A M, Reiner G C, Norman M J, Katzenellenbogen B S

机构信息

Biology Department, Brookhaven National Laboratory, Upton, NY 11973.

出版信息

J Steroid Biochem. 1988;30(1-6):79-88. doi: 10.1016/0022-4731(88)90079-9.

Abstract

To understand the hormonal regulation of plasminogen activators (PAs) in human breast cancer, we have examined the hormonal regulation and properties of PAs in four human breast cancer cell lines that differ markedly in their estrogen receptor (ER) content: MCF-7 cells contain high levels of ER (approx 7 pmol/mg DNA) and their PA activity was increased 3-4-fold by physiological concentrations of estradiol; T47-D and ZR-75-1 cells contain lower levels of ER (0.9 and 2.1 pmol/mg DNA respectively) and their PA activity was also increased 3-4-fold by estradiol. In contrast, MDA-MB-231 cells, which do not contain ER, showed a high level of PA activity that was not modulated by estradiol. SDS-PAGE followed by zymography indicated that MCF-7 cells secreted tissue-type PA (t-PA), T47-D and ZR-75-1 cells secreted urokinase-type PA (u-PA), and MDA-MB-231 cells secreted both types of PAs. The types of PAs secreted by these cell lines did not change upon treatment with estradiol. Dose-response curves for the stimulation of MCF-7 PA activity by different estrogens showed an excellent correlation between affinities of the estrogens for ER and their potency in stimulating PA activity. With a clonal subline of MCF-7 cells, MCF-L, a soluble inhibitor of both t-PA and u-PA was secreted. Incubation of purified t-PA or u-PA with the serum-free conditioned medium from MCF-L cells resulted in a shift in the mobility of t-PA and u-PA in SDS-polyacrylamide gels to forms increased in molecular mass by about 50,000-70,000. The shifts in molecular mass could be prevented by the presence of the competitive inhibitor p-aminobenzamidine, indicating that the active sites of the PAs were involved in the formation of these complexes. Furthermore, co-cultivation, of RT4-D rat neuroblastoma cells, which exhibit high levels of t-PA activity, with MCF-L cells resulted in a marked decrease in the PA activity of the RT4-D cells. Our results were consistent with the following conclusions: t-PA, u-PA or both were secreted by human breast cancer cells. In the ER-containing cell lines, depending upon the specific cell line, t-PA or u-PA was stimulated by estrogens. The unstimulated levels of PA activity and the magnitude of PA stimulation by estrogens were not closely related to ER content.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

为了解人乳腺癌中纤溶酶原激活剂(PAs)的激素调节机制,我们检测了四种雌激素受体(ER)含量差异显著的人乳腺癌细胞系中PAs的激素调节及特性:MCF-7细胞含有高水平的ER(约7 pmol/mg DNA),其PA活性在生理浓度的雌二醇作用下增加3至4倍;T47-D和ZR-75-1细胞含有较低水平的ER(分别为0.9和2.1 pmol/mg DNA),其PA活性也在雌二醇作用下增加3至4倍。相比之下,不含ER的MDA-MB-231细胞显示出高水平的PA活性,且不受雌二醇调节。SDS-PAGE后进行酶谱分析表明,MCF-7细胞分泌组织型PA(t-PA),T47-D和ZR-75-1细胞分泌尿激酶型PA(u-PA),而MDA-MB-231细胞两种类型的PA均分泌。这些细胞系分泌的PA类型在雌二醇处理后未发生变化。不同雌激素刺激MCF-7细胞PA活性的剂量反应曲线显示,雌激素与ER的亲和力及其刺激PA活性的效力之间具有良好的相关性。在MCF-7细胞的一个克隆亚系MCF-L中,分泌了一种t-PA和u-PA的可溶性抑制剂。将纯化的t-PA或u-PA与MCF-L细胞的无血清条件培养基孵育,导致t-PA和u-PA在SDS-聚丙烯酰胺凝胶中的迁移率发生改变,形成分子量增加约50,000 - 70,000的形式。分子量的改变可被竞争性抑制剂对氨基苯甲脒阻止,表明PA的活性位点参与了这些复合物的形成。此外,将具有高水平t-PA活性的RT4-D大鼠神经母细胞瘤细胞与MCF-L细胞共培养,导致RT4-D细胞的PA活性显著降低。我们的结果与以下结论一致:人乳腺癌细胞分泌t-PA、u-PA或两者皆有。在含ER的细胞系中,根据具体细胞系的不同,t-PA或u-PA受雌激素刺激。PA活性的基础水平及雌激素对PA的刺激程度与ER含量无密切关系。(摘要截短至400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验